IN8bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.6M
- Price
- $1.28
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.79%
- Volume
- 105.9K
About
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Quick stats
Shares outstanding9.8M
Computed float7.0M
Float / shares70.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001740279
Websitehttps://in8bio.com
AI Summary
AI-generated1/11
minorneutralother
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio granted a nonqualified stock option to purchase 4,000 shares of common stock to a new employee as an inducement to enter into employment.
The award was approved by the Compensation Committee under the Company's 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The option will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting in equal monthly installments over the following 36 months.